Kiromic BioPharma, Inc. Forms a Collaboration with Bellicum Pharmaceutical
Houston, Texas, Apr. 11, 2017 – Kiromic Inc., today announced that it has initiated a collaboration with Bellicum Pharmaceutical, with the goal of advancing the development of a Kiromic’s Chimeric Antigen Receptor R&D program. The partnership will focus on the development of immunotherapeutics for the treatment of ovarian cancer, triple-negative breast cancer, and multiple myeloma.
About Kiromic Biopharma
Kiromic is a clinical-stage immuno-oncology biopharmaceutical company with a breakthrough artificial intelligence called KAI, and drug discovery programs across multiple technology platforms; including cellular therapies, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.
About Bellicum Pharmaceutical
Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing cellular immunotherapies for orphan inherited blood diseases, hematological cancers, and solid tumors.
For more information, visit www.bellicum.com.